Close Menu

Michael Nemzek

Jan 05, 2017

MedGenome has appointed Michael Nemzek as chief commercial officer. Nemzek has held executive leadership positions in both public companies and private companies, including RareCyte, Affymetrix, and Velocity11. He also holds advanced degrees in chemistry from North Carolina State University and in management from the University of Maryland.

More Like This

Oct 01, 2020

Thrive Earlier Detection: Sam Asgarian, Frank Diehl, Dina Ciarimboli

Thrive Earlier Detection has made three new appointments. Sam Asgarian is its new chief medical officer, Frank Diehl its executive vice president of product solutions, and Dina Ciarimboli has joined the firm full time as chief legal officer following an interim role as general counsel.

Asgarian, who will lead the firm's medical strategy, including the integration of its CancerSEEK early detection test into routine medical care, was most recently vice president of CVS Health’s Transformation Health Product organization. Asgarian joined CVS as part of the Aetna acquisition, having served as the chief medical officer of Aetna'sclinical services organization, overseeing medical management and clinical policy operations. He holds a BA in molecular and cell biology from the University of California at Berkeley, an MA in medical sciences from Loyola University Chicago, an MD from Tulane University, and an MBA from Cornell University.

Diehl is a globally recognized leader in cancer biology and detection who has pioneered the use of circulating tumor DNA to detect and track the progression of cancer. In 2008, he co-founded liquid biopsy fir Inostics, where he served as chief scientific officer through its acquisition by Sysmex, ultimately becoming CEO of Sysmex Inostics. Diehl completed a postdoctoral fellowship at the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University and worked in the laboratory of Thrive co-founders Bert Vogelstein and Kenneth Kinzler. He holds a PhD in molecular pathology from Ruprecht-Karls University in Heidelberg, Germany.

Ciarimboli, prior to joining Thrive full time, was general counsel at Third Rock Ventures. Before that, she served as general counsel to several venture capital firms focused on early stage investing in various industries including biotech, diagnostics, medical devices, and healthcare services. Earlier, she served as an associate at Testa, Hurwitz & Thibeault, LLP and as a senior associate at PricewaterhouseCoopers. Ciarimboli holds a BA in accounting and philosophy from Boston College and completed a JD at Boston College School of Law.

Oct 01, 2020

Oncocyte: Albert Parker, Tony Kalajian, Lyndal Hesterberg

Oncocyte has announced that it has terminated the full-time employment of Albert Parker, its chief operating officer and secretary, Tony Kalajian, its chief accounting officer, and Lyndal Hesterberg, its chief scientific officer, as part of a cost savings plan.

Parker, Kalajian, and Hesterberg each accepted an offer to continue to serve temporarily in their current positions on a part-time "at will" basis under the terms of a reduction in salary agreement, whcih includes a 50 percent cut to the three executives bi-weekly salaries, but allows them to remain eligible to participate in Oncocyte’s employee benefit and equity incetive plans. The firm expects the part-time employment to end on December 18, 2020 although any party may also decide to terminate on an earlier date. 

Sep 29, 2020

BioAffinity Technologies: Martin Tammemägi

BioAffinity Technologies announced Martin Tammemägi will become chairman of the company's scientific and medical advisory board. He was a co-investigator and remains active in the US Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, the US National Lung Screening Trial, and the Pan-Canadian Early Detection of Lung Cancer Study. He is an active associate member of the US National Institutes of Health National Cancer Institute Cancer Intervention and Surveillance Modeling Network lung group and is the provincial scientific lead for Ontario Health - Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk.

Sep 24, 2020

GenMark Diagnostics: Brian Mitchell

GenMark Diagnostics said in a filing with the US Securities and Exchange Commission that Brian Mitchell, its senior vice president of operations, is no longer employed by the company.

Sep 22, 2020

Exact Sciences: Eli Casdin

In a filing with the US Securities and Exchange Comission, Exact Sciences said that board member Eli Casdin had submitted his resignation from the company's board of directors, effective Sept. 21. Casdin is the chief investment officer and founder of Casdin Capital, an investment firm focused on the life sciences and healthcare industry.

Sep 22, 2020

Inivata: Peter Collins

Inivata has appointed Peter Collins as the firm's chief business officer. Prior to Inivata, Collins most recently held senior leadership positions at Guardant Health. He has also served as chief business officer at Yourgene Health. Prior to Yourgene, Collins served as VP, head of diagnostics at GSK, as well as VP of pharma business development at Qiagen. He was also the founder and board member of Epemed. 

Sep 18, 2020

Quidel: Robert Bujarski

Quidel has appointed Robert Bujarski as chief operating officer effective Sept. 14. Bujarski had been Quidel's SVP of commercial operations in North America and general counsel since July 2019, SVP of business development from August 2009 through July 2019, and corporate secretary until February 2019.

Sep 17, 2020

iAssay: Edward Strong

Edward Strong has been named scientific director of iAssay, a firm developing an open platform that consolidates utilization of a range of point-of-care tests with a single cloud-connected, handheld reader. Strong, a geneticist, formerly cofounded and served as CEO of MedGenomics, and also served as interim CEO of LifeGenomix.

Sep 17, 2020

Biofidelity: Stephen Miller

Biofidelity has appointed Stephen Miller as chief commercial officer. Miller has held leadership positions at both public and private companies including Precipio, BG Medicine, Thermo Fisher Scientific, and Athena Diagnostics.

Sep 16, 2020

Magnolia Medical Technologies: Richard Ivey, Paul Goldenbaum

Magnolia Medical Technologies has appointed two former Becton Dickinson senior executives to its medical and scientific advisory board. They are Richard Ivey, retired worldwide vice president of research and development for Becton Dickinson's life sciences diagnostic systems business, and Paul Goldenbaum, retired director of research and development for BD's diagnostic instrument systems division.

With BD, Ivey led an R&D team of several hundred engineers and scientists focused on diagnostic technologies, including infectious disease diagnostic instrumentation, laboratory automation engineering, microbiology, molecular biology, immunochemistry, and cytology.

With BD, Goldenbaum was charged with improving and expanding the Bactec blood culture media product line for sepsis testing. In this role, he developed the blood culture media for all generations of the Bactec blood culture system including radiometric, resin media, non-radiometric, and the current fluorescent, non-invasive media.

Sep 16, 2020

Gravity Diagnostics: Mary Talbott

Gravity Diagnostics has hired Mary Talbott as chief legal secretary and secretary. Talbott has more than 25 years of experience in corporate and private practice and most recently was senior vice president, general counsel, and corporate secretary for Tennant Company. Before that, she was VP, assistant general counsel, and assistant corporate secretary for General Cable. Gravity Dx is a full-service CLIA laboratory based in Covington, Kentucky and provides testing services in infectious diseases, toxicology, and pharmacogenomics.

Sep 15, 2020

Alveo Technologies: Fran Soistman

Fran Soistman has joined the scientific board of Alveo Technologies. He has more than 40 years of experience in the healthcare and managed care sector, including as executive vice president for Aetna. As a member of Alveo's scientific advisory board, Soistman will help guide the firm's efforts to implement its infectious disease testing technologies. Alameda, California-based Alveo is developing its be.well platform, a point-of-care, at-home diagnostic tool.

Sep 15, 2020

NeoGenomics: Madhushree Ghosh

NeoGenomics announced that Madhushree Ghosh has joined the company as VP of alliances and companion diagnostics. She previously served as the senior director of strategic accounts and global strategic partnerships at Thermo Fisher Scientific. She has also served as VP of alliance management and VP of the research services business unit at Althea Dx, as well as in senior leadership positions at Qiagen and Enigma Diagnostics. Ghosh has expertise in next-generation sequencing, multiplex and real-time PCR, oncology, and infectious diseases.

Sep 14, 2020

Veracyte: Richard Kloos

Veracyte has promoted Richard Kloos to executive medical director, overseeing the company's global medical affairs in all clinical areas addressed by its genomic tests. Kloos previously served as senior medical director of endocrinology at Veracyte, which he joined in 2012. He was previously a professor of endocrinology and metabolism, and nuclear medicine at Ohio State University, and was attending physician at the OSU Comprehensive Care Center. He was also codirector of the OSU Thyroid Cancer Unit and served a four-year term as secretary and chief operating officer for the American Thyroid Association.

Sep 14, 2020

Thermo Fisher Scientific: Joseph Holmes, Peter Hornstra

Joseph Holmes has been elected as VP and chief accounting officer of Thermo Fisher Scientific, effective March 31, 2021. He will succeed Peter Hornstra, who will retire from the company March 31. Holmes is currently senior director of technical accounting at Thermo Fisher, a position he assumed when he joined the company in 2017. Previously, he was director of technical accounting and reporting at St. Jude Medical, which was acquired by Abbott Laboratories in 2017.